Published in Br J Cancer on July 06, 2001
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res (2007) 2.46
Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci U S A (2006) 1.99
Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res (2005) 1.45
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer (2004) 1.41
The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2004) 1.04
Androgen receptor as a targeted therapy for breast cancer. Am J Cancer Res (2012) 1.04
The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res (2003) 0.97
A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Res (2006) 0.97
Unique SNP in CD44 intron 1 and its role in breast cancer development. Anticancer Res (2010) 0.91
Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers. Br J Cancer (2008) 0.87
Selected estrogen receptor 1 and androgen receptor gene polymorphisms in relation to risk of breast cancer and fibrocystic breast conditions among Chinese women. Cancer Epidemiol (2010) 0.85
Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk. BMC Cancer (2011) 0.83
Androgen receptor status predicts response to chemotherapy, not risk of breast cancer in Indian women. World J Surg Oncol (2010) 0.83
Microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian women. PLoS One (2012) 0.79
Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin. Fam Cancer (2008) 0.79
Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Fam Cancer (2008) 0.78
Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer. J Cancer Res Clin Oncol (2006) 0.77
Association of androgen receptor GGN repeat length polymorphism and male infertility in Khuzestan, Iran. Iran J Reprod Med (2015) 0.75
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature (1991) 9.89
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 9.06
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst (1999) 6.48
Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics (1992) 6.40
Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet (1998) 3.61
Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst (1997) 2.74
Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med (1999) 2.43
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet (1999) 2.14
Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet (1995) 1.91
Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet (1971) 1.66
Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol (1993) 1.47
Trinucleotide repeat polymorphism in the androgen receptor gene (AR). Nucleic Acids Res (1992) 1.34
The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer (1996) 1.34
No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis (1999) 1.21
Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res (1997) 1.14
Androgens and breast cancer in premenopausal women. Cancer Res (1989) 1.03
Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. J Natl Cancer Inst (1999) 1.03
Serum and urinary androgens and risk of breast cancer in postmenopausal women. Cancer Res (1991) 1.02
Adrenal androgens and human breast cancer: a new appraisal. Breast Cancer Res Treat (1998) 0.96
Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer (1999) 0.94
Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum Mol Genet (1993) 0.93
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Experimental annotation of the human genome using microarray technology. Nature (2001) 10.39
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet (2004) 9.10
Genetic inheritance of gene expression in human cell lines. Am J Hum Genet (2004) 8.97
Survival of patients with breast cancer attending Bristol Cancer Help Centre. Lancet (1990) 7.04
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst (1999) 6.48
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst (1994) 6.27
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet (2005) 6.18
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet (1995) 5.83
Expression of flagellar genes carried by bacteriophage lambda. Nature (1976) 5.14
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet (1998) 4.72
Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer (1997) 4.47
Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nat Genet (1997) 4.43
Adenosine diphosphate as an intracellular regulator of insulin secretion. Science (1996) 4.42
Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst (2000) 4.39
Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med (1999) 4.22
Monitoring clinical trials--interim data should be publicly available. BMJ (2001) 4.20
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18
The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer (2004) 4.06
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet (1995) 3.71
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet (1994) 3.38
Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev (1999) 3.29
Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine (1998) 3.16
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet (1992) 3.13
Energy balance and colon cancer--beyond physical activity. Cancer Res (1997) 3.11
How many more breast cancer predisposition genes are there? Breast Cancer Res (1999) 3.10
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09
Genes, themes and microarrays: using information retrieval for large-scale gene analysis. Proc Int Conf Intell Syst Mol Biol (2000) 3.01
Bacterial community dynamics across a floristic gradient in a temperate upland grassland ecosystem. Microb Ecol (2002) 2.99
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet (1996) 2.97
Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene (1995) 2.91
A recessive contiguous gene deletion causing infantile hyperinsulinism, enteropathy and deafness identifies the Usher type 1C gene. Nat Genet (2000) 2.87
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet (2008) 2.81
Risk models for familial ovarian and breast cancer. Genet Epidemiol (2000) 2.75
Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes (2000) 2.75
Models of genetic susceptibility to breast cancer. Oncogene (2006) 2.69
The bases of practice--neurological physiotherapy. Physiother Res Int (1996) 2.52
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res (1996) 2.43
A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev (1999) 2.39
Familial hyperinsulinism with apparent autosomal dominant inheritance: clinical and genetic differences from the autosomal recessive variant. J Pediatr (1998) 2.33
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer (2011) 2.28
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet (1997) 2.28
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
Mycobacterium bovis infection in human beings in contact with elk (Cervus elaphus) in Alberta, Canada. Lancet (1991) 2.20
Prophylactic nasogastric decompression after abdominal surgery. Cochrane Database Syst Rev (2007) 2.18
A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature (1987) 2.15
ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet (1998) 2.06
Physical activity and colorectal cancer. Am J Epidemiol (2003) 2.04
The extent of linkage disequilibrium in four populations with distinct demographic histories. Am J Hum Genet (2000) 2.03
"Fast tracking" patients with a proximal femoral fracture. J Accid Emerg Med (1996) 1.99
Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care (1997) 1.99
Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol (2000) 1.98
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology (2006) 1.98
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Sporadic imprinting defects in Prader-Willi syndrome and Angelman syndrome: implications for imprint-switch models, genetic counseling, and prenatal diagnosis. Am J Hum Genet (1998) 1.87
BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer (2011) 1.86
A prospective cohort of American Indian and Alaska Native people: study design, methods, and implementation. Am J Epidemiol (2007) 1.86
A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism. Diabetes (1997) 1.86
Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. Am J Hum Genet (2001) 1.82
Rethinking sexual health clinics. Patients prefer clinics to have non-descriptive titles. BMJ (1995) 1.81
A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet (2000) 1.80
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
The genetics of breast and ovarian cancer. Br J Cancer (1995) 1.78
Mutations in the sulonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews. Hum Mol Genet (1996) 1.76
Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control (1997) 1.75
BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet (1995) 1.75
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med (2006) 1.73
Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis. Dement Geriatr Cogn Disord (1999) 1.73
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet (1994) 1.71
CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst (2000) 1.69
Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol (2001) 1.69
Presymptomatic screening for multiple endocrine neoplasia type 2A with linked DNA markers. The MEN 2A International Collaborative Group. Lancet (1991) 1.68
Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res (2001) 1.67
Basement membrane collagen: degradation by migrating endothelial cells. Science (1983) 1.67
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer (2008) 1.62
Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med (2012) 1.60
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int (2010) 1.60
Contamination of environmental surfaces by genital human papillomaviruses. Sex Transm Infect (2002) 1.60
Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol (1996) 1.59
Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy. Diabetes (1998) 1.59
Contribution of Malate and Amino Acid Metabolism to Cytoplasmic pH Regulation in Hypoxic Maize Root Tips Studied Using Nuclear Magnetic Resonance Spectroscopy. Plant Physiol (1992) 1.59
Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes (1998) 1.53
Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol (2000) 1.52
Selective receptor blockade during phagocytosis does not alter the survival and growth of Mycobacterium tuberculosis in human macrophages. Am J Respir Cell Mol Biol (1996) 1.52
Germline PTEN mutations in Cowden syndrome-like families. J Med Genet (1998) 1.51
Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res (1999) 1.51
Born too late to win? Nature (1994) 1.51